The interplay between cytogenetic profile and prognostic power of specific mutations is highlighted by the finding that most MDS patients presenting with a complex karyotype also carry a mutation or a deletion in the well-known tumor suppresser gene TP53. 43,44 Whether the aberrant karyotype or the TP53 mutation is responsible for the poor outcome of affected patients is still unknown. Here, TP53 is linked to neoplasm.